deucravacitinib news

All news on deucravacitinib (also known as BMS-986165 and Sotyktu): plants, production capacities, investments and involved companies.

11 June 2026

Takeda's zasocitinib outperforms deucravacitinib in Phase 3 psoriasis head-to-head

Once-daily oral TYK2 inhibitor showed statistical superiority to deucravacitinib for PASI100 and key secondary endpoints, with >35% achieving complete skin clearance at week 16.

Who will be producing deucravacitinib in the future?

Find out with chemXplore Alpha

Learn more